首页> 外文期刊>Tissue engineering, Part A >A Nanomedicine Approach to Effectively Inhibit Contracture During Bladder Acellular Matrix Allograft-Induced Bladder Regeneration by Sustained Delivery of Vascular Endothelial Growth Factor
【24h】

A Nanomedicine Approach to Effectively Inhibit Contracture During Bladder Acellular Matrix Allograft-Induced Bladder Regeneration by Sustained Delivery of Vascular Endothelial Growth Factor

机译:通过持续递送血管内皮生长因子有效抑制膀胱脱细胞基质同种异体移植诱导的膀胱再生期间挛缩的纳米医学方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Macroscopic evidence of contracture has been identified as a major issue during the regeneration process. We hypothesize that lack of angiogenesis is the primary cause of contracture and explore a nanomedicine approach to achieve sustained release of vascular endothelial growth factor (VEGF) to stimulate angiogenesis. We evaluate the efficacy of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for long-term (3 months) sustained release of VEGF in bladder acellular matrix allografts (BAMA) in a swine model. We anticipate that the sustained release of VEGF could stimulate angiogenesis along the regeneration process and thereby inhibit contracture. Bladder was replaced with BAMA (5x5 cm), modified with PLGA NPs encapsulated with VEGF in a pig model. The time points chosen for sampling were 1, 2, 4, and 12 weeks. The regenerated areas were then measured to obtain the contracture rate, and the extent of revascularization was calculated using histological and morphological features. In the control group of animals, the bladder was replaced with only BAMA. The in vivo release of VEGF was evident for similar to 3 months, achieving the goal of long-acting sustained release, and successfully promoted the regeneration of blood vessels and smooth muscle fibers. In addition, less collagen deposition was observed in the experimental group compared with control. Most importantly, the inhibition of contracture was highly significant, and the ultimate contracture rate decreased by similar to 57% in the experimental group compared with control. In isolated strips analysis, there were no significant differences between BAMA-regenerated (either VEGF added or not) and autogenous bladder. BAMA modified with VEGF-loaded PLGA-NPs can sustainably release VEGF in vivo (>3 months) to stimulate angiogenesis leading to the inhibition of contracture. This is the first study to report a viable nanomedicine-based strategy to overcome contracture during bladder regeneration induced by BAMA. Furthermore, this study also confirms that insufficient angiogenesis plays a crucial role in the onset of contracture.
机译:挛缩的宏观证据已被确定为再生过程中的主要问题。我们假设缺乏血管生成是挛缩的主要原因,并探索一种纳米药物方法来实现持续释放血管内皮生长因子(VEGF)来刺激血管生成。我们评估猪模型中的膀胱无细胞基质同种异体移植物(BAMA)中长期(3个月)持续释放VEGF的聚乳酸-乙醇酸共聚物(PLGA)纳米粒子(NPs)的功效。我们预计VEGF的持续释放可以刺激再生过程中的血管生成,从而抑制挛缩。在猪模型中,将膀胱替换为BAMA(5x5厘米),并用包裹有VEGF的PLGA NP修饰膀胱。选择采样的时间点是1、2、4和12周。然后测量再生区域以获得挛缩率,并使用组织学和形态学特征计算血运重建的程度。在对照组动物中,仅用BAMA代替了膀胱。 VEGF的体内释放在大约3个月内是明显的,达到了长效持续释放的目的,并成功地促进了血管和平滑肌纤维的再生。另外,与对照组相比,在实验组中观察到更少的胶原蛋白沉积。最重要的是,挛缩的抑制作用非常显着,与对照组相比,实验组的最终挛缩率降低了约57%。在分离的条带分析中,BAMA再生(添加或不添加VEGF)与自体膀胱之间无显着差异。用载有VEGF的PLGA-NP修饰的BAMA可以在体内(> 3个月)持续释放VEGF,以刺激血管生成,从而导致挛缩的抑制。这是第一个报告基于可行的基于纳米药物的策略来克服BAMA诱导的膀胱再生过程中挛缩的研究。此外,该研究还证实血管生成不足在挛缩发作中起关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号